Article

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.

GlaxoSmithKline Biologicals, Rixensart, Belgium.
The Journal of Immunology (Impact Factor: 5.52). 11/2009; 183(10):6186-97. DOI: 10.4049/jimmunol.0901474
Source: PubMed

ABSTRACT Adjuvant System 04 (AS04) combines the TLR4 agonist MPL (3-O-desacyl-4'-monophosphoryl lipid A) and aluminum salt. It is a new generation TLR-based adjuvant licensed for use in human vaccines. One of these vaccines, the human papillomavirus (HPV) vaccine Cervarix, is used in this study to elucidate the mechanism of action of AS04 in human cells and in mice. The adjuvant activity of AS04 was found to be strictly dependent on AS04 and the HPV Ags being injected at the same i.m. site within 24 h of each other. During this period, AS04 transiently induced local NF-kappaB activity and cytokine production. This led to an increased number of activated Ag-loaded dendritic cells and monocytes in the lymph node draining the injection site, which further increased the activation of Ag-specific T cells. AS04 was also found to directly stimulate those APCs in vitro but not directly stimulate CD4(+) T or B lymphocytes. These AS04-induced innate responses were primarily due to MPL. Aluminum salt appeared not to synergize with or inhibit MPL, but rather it prolonged the cytokine responses to MPL at the injection site. Altogether these results support a model in which the addition of MPL to aluminum salt enhances the vaccine response by rapidly triggering a local cytokine response leading to an optimal activation of APCs. The transient and confined nature of these responses provides further supporting evidence for the favorable safety profile of AS04 adjuvanted vaccines.

0 Bookmarks
 · 
205 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumen La resistencia a los antibióticos se ha convertido en uno de los principales problemas de salud. El combatir a los organismos patógenos con terapias combinadas que involucren la participación del sistema inmune y de fármacos antimicrobianos, representa un modelo exitoso para el tratamiento de enfermedades infecciosas agudas y crónicas. La presente revisión de inmunomoduladores de origen bacteriano, eucariótico y farmaco-lógico, muestra que pueden estimular los mecanismos de defensa del hospedero contra diversas enfermedades virales, bacterianas, parasíticas y fúngicas. El potencial de estos agentes para modular la respuesta inmune puede ser utilizado como tratamiento o como terapia adyuvante de diversas enfermedades microbianas. Immunomodulators as an adjuvant therapy in infectious diseases
    Medicina Universitaria. 10/2009; 11(45):247-259.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Innate immunity confers an immediate nonspecific mechanism of microbial recognition through germ line-encoded pattern recognition receptors (PRRs). Of these, Toll-like receptors (TLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) have shaped our current understanding of innate regulation of adaptive immunity. It is now recognized that PRRs are paramount in instructing an appropriate adaptive immune response. Their ligands have been the focus of adjuvant research with the goal of generating modern vaccine combinations tailored to specific pathogens. In this review we will highlight the recent findings in the field of adjuvant research with a particular focus on the potential of TLR and NLR ligands as adjuvants and their influence on adaptive immune responses.
    Proceedings of the National Academy of Sciences of the United States of America. 08/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eradication of smallpox and discontinuation of the vaccination campaign resulted in an increase in the percentage of unvaccinated individuals, highlighting the need for postexposure efficient countermeasures in case of accidental or deliberate viral release. Intranasal infection of mice with ectromelia virus (ECTV), a model for human smallpox, is curable by vaccination with a high vaccine dose given up to 3 days postexposure. To further extend this protective window and to reduce morbidity, mice were vaccinated postexposure with Vaccinia-Lister, the conventional smallpox vaccine or Modified Vaccinia Ankara, a highly attenuated vaccine in conjunction with TLR3 or TLR9 agonists. We show that co-administration of the TLR3 agonist poly(I:C) even 5 days postexposure conferred protection, avoiding the need to increase the vaccination dose. Efficacious treatments prevented death, ameliorated disease symptoms, reduced viral load and maintained tissue integrity of target organs. Protection was associated with significant elevation of serum IFNα and anti-vaccinia IgM antibodies, modulation of IFNγ response, and balanced activation of NK and T cells. TLR9 agonists (CpG ODNs) were less protective than the TLR3 agonist poly(I:C). We show that activation of type 1 IFN by poly(I:C) and protection is achievable even without co-vaccination, requiring sufficient amount of the viral antigens of the infective agent or the vaccine. This study demonstrated the therapeutic potential of postexposure immune modulation by TLR activation, allowing to alleviate the disease symptoms and to further extend the protective window of postexposure vaccination.
    PLoS ONE 01/2014; 9(10):e110545. · 3.53 Impact Factor

Full-text (2 Sources)

Download
44 Downloads
Available from
May 21, 2014